Sequential scintigraphic strategy for the differentiation of brain tumours
- PMID: 10853811
- DOI: 10.1007/s002590050542
Sequential scintigraphic strategy for the differentiation of brain tumours
Abstract
Both thallium-201 and iodine-123 alpha-methyltyrosine (123I-IMT) have been shown to be useful in the diagnostic evaluation of brain tumours. The aim of this study was to investigate the respective contributions of 201Tl and 123I-IMT single-photon emission tomography (SPET) in the non-invasive evaluation of intracerebral tumours. We analysed 65 patients with the following brain tumours: 8 non-neoplastic lesions, 4 meningiomas, 12 low-grade gliomas, 28 high-grade gliomas, 11 metastases and 2 high-grade lymphomas. 201Tl SPET and 123I-IMT SPET were performed [start of 201Tl SPET: 15 min p.i. (early) and 180 min p.i. (delayed); start of 123I-IMT SPET: 15 min p.i.]. The intensity of uptake was quantified as the ratio between tracer accumulation in the tumour and in the contralateral hemisphere. None of the non-neoplastic lesions or low-grade gliomas expressed marked 201Tl uptake. All malignant tumours except one small metastasis and all meningiomas except one small, cystic and degenerated lesion showed significant 201Tl accumulation [Tl(15')>2.0]; 123I-IMT uptake was either absent or intermediate in non-malignant lesions except in two low-grade gliomas; the highest levels were observed in high-grade gliomas followed by metastases and lymphomas (mean IMT: 2.7 vs. 2.1 vs. 1.8), with metastases showing a high variability in 123I-IMT uptake (range: 0.8-3.6). Using 201Tl to distinguish non-neoplastic lesions from malignant tumours and meningiomas, 63 of 65 patients were characterised correctly. In the latter group, high-grade gliomas were correctly identified in 27 of 28 cases by their amino acid uptake. It is concluded that the combination of 201Tl and 123I-IMT surpasses the accuracy of each single test in the differentiation of space-occupying lesions of the brain. Based on these preliminary results, a sequential strategy is proposed involving an initial 201Tl SPET study and an additional 123I-IMT SPET study in the event of positive 201Tl uptake.
Similar articles
-
3-[123I]Iodo-alpha-methyl-L-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis.Eur J Nucl Med. 2001 Jul;28(7):855-61. doi: 10.1007/s002590100553. Eur J Nucl Med. 2001. PMID: 11504082
-
Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.Eur J Nucl Med. 1999 Feb;26(2):144-51. doi: 10.1007/s002590050370. Eur J Nucl Med. 1999. PMID: 9933348
-
Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose.Eur J Nucl Med. 1997 Apr;24(4):428-34. doi: 10.1007/BF00881816. Eur J Nucl Med. 1997. PMID: 9096095
-
[The role of L-3-I-123-iodine-alpha-methyltyrosine SPECT in cerebral gliomas].Nuklearmedizin. 2000 Dec;39(8):233-40. Nuklearmedizin. 2000. PMID: 11189900 Review. German.
-
Imaging gliomas with positron emission tomography and single-photon emission computed tomography.Semin Nucl Med. 2003 Apr;33(2):148-62. doi: 10.1053/snuc.2003.127304. Semin Nucl Med. 2003. PMID: 12756647 Review.
Cited by
-
123I-IMT SPET: introducing another research tool into clinical neuro-oncology?Eur J Nucl Med. 2001 Jan;28(1):1-4. doi: 10.1007/s002590000352. Eur J Nucl Med. 2001. PMID: 11202443 Review. No abstract available.
-
Prospective study of p-[123I]iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions: specific confirmation of glioma.Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2344-53. doi: 10.1007/s00259-010-1572-4. Epub 2010 Jul 30. Eur J Nucl Med Mol Imaging. 2010. PMID: 20676638
-
Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT.Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1041-9. doi: 10.1007/s00259-005-1807-y. Epub 2005 May 18. Eur J Nucl Med Mol Imaging. 2005. PMID: 15902439 Clinical Trial.
-
O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours.Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9. doi: 10.1007/s00259-004-1705-8. Epub 2005 Jan 14. Eur J Nucl Med Mol Imaging. 2005. PMID: 15650870 Clinical Trial.
-
Flat-panel detector-based volume computed tomography: a novel 3D imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model.Neoplasia. 2007 Sep;9(9):755-65. doi: 10.1593/neo.07466. Neoplasia. 2007. PMID: 17898871 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical